Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers

Cancer Treatment and Research Communications · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles